AARD stock forecast, quote, news & analysis
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases... Show more
Why Aardvark Therapeutics (AARD) Stock Is Down 78% in the Last 30 Days
Key Takeaways
- AARD shares have fallen roughly 78% over the last 30 days, driven primarily by a single-session plunge of about 65% on October 23 after exploratory Phase 3 HERO data for ARD-101 disappointed investors.
- The terminated HERO trial (67 of a planned 90 participants) showed only modest reductions in hyperphagia scores that largely reversed after treatment stopped, leaving the Prader-Willi Syndrome program without definitive efficacy data.
- The selloff followed the U.S. FDA lifting its full clinical hold on ARD-101 on October 22, a positive milestone that was quickly overshadowed by the weak efficacy readout.
- Over the last quarter the decline is even steeper, with shares losing the vast majority of their value from earlier-2026 levels amid a voluntary dosing pause, an FDA clinical hold, and mounting clinical uncertainty.
- Analysts have tempered their views: Morgan Stanley maintains a Sell rating with a $3 target, while H.C. Wainwright cut its price target to $2 from $4 after the data.
- Aardvark plans to request an FDA meeting to align on a new Phase 3 trial design, with PWS clinical activities not expected to resume until 2027.
- For additional detail on this ticker's Price Targets, Earnings, and Forecast, explore the dedicated pages.
- Explore Trending AI Robots to see how AI-driven trading strategies are approaching stocks like AARD.
Aardvark Therapeutics (AARD) Company Overview and Market Position
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, and founded in 2017. The company develops oral, small-molecule therapeutics designed to activate innate homeostatic pathways that suppress hunger, with a focus on Prader-Willi Syndrome (PWS) and metabolic diseases.
Its lead candidate, ARD-101 (denatonium acetate monohydrate), is an oral, gut-restricted agonist of bitter taste receptors (TAS2Rs) expressed in the gut lumen, which participate in the gut-brain axis and the body's natural satiety signaling. The company has also been developing ARD-201, a fixed-dose combination of ARD-101 with a DPP-4 inhibitor, aimed at addressing limitations of marketed GLP-1 therapies for obesity and weight regain. As a pre-revenue, development-stage company, AARD's valuation is driven almost entirely by clinical data, regulatory milestones, and its cash position rather than current financial results.
Aardvark Therapeutics (AARD) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, AARD shares have dropped approximately 78%, sliding from around $5.06 in late September to roughly $1.09 in late October. The bulk of that decline occurred in a single trading session on October 23, when the stock fell about 65% in one day, from a prior close of $3.95 to $1.39, touching a fresh 52-week low.
The quarterly picture is even more severe. The shares traded near $6.80 in late August, meaning the stock has lost roughly 84% over that span, and it has surrendered the vast majority of its value from the 52-week high of $16.60 reached earlier in 2026. The sustained downtrend reflects a series of setbacks stretching back to early 2026 rather than a single isolated event.
What Drove AARD Stock Price in the Last 30 Days
The decisive catalyst was the October 23 release of exploratory efficacy data from the previously terminated Phase 3 HERO trial and its open-label extension (OLE) evaluating ARD-101 for hyperphagia associated with PWS. Because the trial was stopped after randomizing only 67 of the planned 90 participants, the company itself characterized all efficacy data as exploratory and non-definitive. Results showed only a modest reduction in Hyperphagia Questionnaire for Clinical Trials (HQ-CT) scores versus placebo by week two of dose escalation, and scores returned to near baseline within two weeks of stopping treatment, while the placebo group showed less rebound.
The disappointment was amplified by the timing. On October 22, the FDA lifted the full clinical hold that had been placed on ARD-101's Investigational New Drug application in May 2026, triggering a brief relief rally. The subsequent data readout, however, indicated that any path to market would require a redesigned Phase 3 trial, additional time, and further capital. The selloff pushed AARD's market capitalization below its cash balance, and the company now trades near the bottom of its 52-week range.
What Drove AARD Stock Performance Over the Last Quarter
The quarterly decline reflects a longer-running sequence of clinical and regulatory setbacks. In February 2026, Aardvark voluntarily paused dosing in the Phase 3 HERO and OLE trials after reversible electrocardiogram (ECG) changes were observed in a separate healthy-volunteer study. In May 2026, the FDA placed a full clinical hold on the ARD-101 program. By August, the company had unblinded the accumulated data and indicated it no longer planned to complete either trial as originally designed.
These developments weighed on sentiment throughout the quarter, compounded by federal securities class action lawsuits alleging that the company's IPO disclosures misrepresented ARD-101's safety profile and clinical trajectory. Although the FDA lifted the hold in October, the subsequent weak efficacy data underscored the uncertainty that has defined the stock's multi-month downtrend.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of the platform's top-performing AI trading bots. Tickeron offers hundreds of AI-driven trading bots that monitor thousands of tickers, but only the most relevant and highest-performing strategies appear in this featured section. These bots vary widely in trading style, timeframe, and performance metrics, giving users insight into how algorithmic approaches are navigating volatile names like AARD. The page provides a neutral, data-oriented window into how quantitative systems respond to fast-moving market conditions and can serve as a useful reference for those researching automated trading strategies.
AARD Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor several factors in the months ahead. The most immediate is Aardvark's planned meeting with the FDA to align on a new Phase 3 trial design for ARD-101, since the company has said it does not expect to resume PWS clinical activities until 2027. Upcoming quarterly earnings, reported on November 12, 2026, will provide an updated cash runway and spending outlook, a critical consideration given that the company's market capitalization has fallen below its reported cash balance.
Additional items to watch include the status of the ARD-201 obesity program, which was also paused, the progression of the pending securities litigation, and any further analyst rating changes. As with all clinical-stage biotechs, the company's outlook hinges on clinical execution, regulatory alignment, and its ability to fund continued development without excessive dilution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AARD in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 23, 2026
AARD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 7 of 8 cases where AARD's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AARD's RSI Indicator exited the oversold zone, 7 of 9 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 13 of 17 cases where AARD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on AARD as a result. In 21 of 25 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for AARD just turned positive on November 10, 2026. Looking at past instances where AARD's MACD turned positive, the stock continued to rise in 14 of 17 cases over the following month. The odds of a continued upward trend are 82%.
Following a +17.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where AARD advanced for three days, in 88 of 102 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AARD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for AARD entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.342) is normal, around the industry mean (3.498). P/E Ratio (-0.363) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. AARD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AARD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology